英夫利西单抗的使用与类风湿关节炎患者的颈椎畸形
本研究基于BeSt试验数据,以新发类风湿关节炎患者为对象开展病例对照研究,评估10年随访期间英夫利西单抗使用时长与颈椎畸形(寰枢椎半脱位和/或枢椎下半脱位>2 mm)的关联。272例患者中108例(40%)出现颈椎畸形,英夫利西单抗使用时长每增加1年,颈椎畸形风险降低11%(OR:0.89,95%CI:0.81至0.98;p=0.02)。中介分析未能揭示DAS44对该关联的影响。
要点
- 272例新发类风湿关节炎患者中108例(40%)在10年随访时出现颈椎畸形。
- 英夫利西单抗使用时长每增加1年,颈椎畸形风险降低11%(OR:0.89,95%CI:0.81至0.98;p=0.02)。
- 中介分析未能揭示DAS44对英夫利西单抗使用与颈椎结局之间关联的影响。
核心结论
- 有证据表明,在10年随访后,较长的英夫利西单抗使用时长与颈椎畸形之间存在有利关联。
- 在持续使用英夫利西单抗时,需要权衡该药对关节以及可能对颈椎的有利效应与潜在不良事件。
研究设计与样本
- 研究为病例对照研究,使用BeSt试验数据,纳入新发类风湿关节炎患者。
- 评估10年随访期间英夫利西单抗的使用时长,暴露缺失值采用末次观测值结转法填补。
- 在5年和10年随访时通过侧位X线评估寰枢椎半脱位和枢椎下半脱位。
- 采用多因素logistic回归模型估计OR及其95%CI,模型校正年龄、性别、基线DAS44、ACPA阳性和类风湿因子阳性。
- 进行中介分析以评估潜在关联是否通过平均DAS44介导。
主要发现
- 272例患者中108例(40%)观察到颈椎畸形(寰枢椎半脱位和/或枢椎下半脱位>2 mm)。
- 英夫利西单抗使用时长每增加1年,颈椎畸形的比值降低11%(OR:0.89,95%CI:0.81至0.98;p=0.02)。
- 中介分析未能揭示DAS44对英夫利西单抗使用与颈椎结局之间关联的影响。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Over the past decades, the incidence of surgery for rheumatoid arthritis (RA)-associated cervical spine deformity decreased. Infliximab has been observed as a protective treatment for joint damage in hands and feet; yet, the protective association between infliximab and the cervical spine has been uncertain. METHODS: Duration of infliximab use during 10 years of follow-up was evaluated in patients with new-onset RA (case control study using data from the BeSt Trial). Missing values on the exposure were imputed using last observation carried forward. Lateral X-rays at 5-year and 10-year follow-ups were assessed for atlantoaxial subluxation (AAS) and subaxial subluxation (SAS). Multiple logistic regression models adjusted for age, gender, baseline Disease Activity Score (DAS44), ACPA-positivity and rheumatoid factor-positivity were used to estimate ORs and their 95% CIs. Mediation analysis was performed to evaluate whether a potential association was mediated via mean DAS44. RESULTS: Cervical deformity (AAS and/or SAS>2 mm) was observed in 108 (40%) of 272 patients. There was an 11% reduction in odds for cervical spine deformity (OR: 0.89, 95% CI: 0.81 to 0.98; p=0.02) for every 1-year increase in duration of infliximab use. Mediation analysis could not reveal an influence of DAS44 on the association between infliximab use and cervical spine outcomes. CONCLUSIONS: There was evidence of a beneficial association between longer duration of use of infliximab and cervical spine deformity after 10 years follow-up. Thus, it is important to balance the favourable effects of infliximab use for the joints and possibly the cervical spine with the potential adverse events of this medication when used continuously. TRIAL REGISTRATION NUMBER: Netherlands Trial Register Number: NTR262.
引用
- Lebouille-Veldman AB, Huizinga TWJ, Mekary RA, et al. Infliximab use and cervical spine deformity in patients with rheumatoid arthritis. RMD Open. 2025. PMID: 40102025. doi:10.1136/rmdopen-2024-005237
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。